Fuji Pharma Co., Ltd.

4554

JP3816200004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 29/05/2024 am IST			5-day change	1st Jan Change
1,457 ^JPY	-1.15%		-4.02%	-16.22%

2023	Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump	MT
2023	Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan	MT

Fuji Pharma Co., Ltd. authorizes a Buyback Plan.

February 09, 2021

The Board of Directors of Fuji Pharma Co., Ltd. has authorized a buyback plan on February 9, 2021.

Latest news about Fuji Pharma Co., Ltd.

Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump	23/23/23	MT
Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan	25/23/25	MT
Alvotech, Fuji Pharma Win Marketing Approval in Japan for Stelara Biosimilar	25/23/25	MT
Vistagen Therapeutics, Fuji Pharma Sign Exclusive Negotiation Deal for Japanese Market	05/23/05	MT
Vistagen and Fuji Pharma Co., Ltd. Enter Exclusive Negotiation Agreement for Potential License to Develop and Commercialize Vistagen?s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan	05/23/05	CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	15/23/15	CI
Mithra Receives Milestone Payment from Fuji Pharma; Shares Surge 11%	03/23/03	MT
Fuji Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended March 31, 2023	11/23/11	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	13/23/13	MT
Alvotech, Fuji Pharma Include New Biosimilar Candidate in Marketing Partnership in Japan	13/23/13	MT
Alvotech and Fuji Pharma Expands Partnership Adding A New Biosimilar Candidate	13/23/13	CI
Alvotech Says Partner Fuji Pharma Submitted Application for Marketing Approval of Biosimilar Candidate in Japan	17/22/17	MT
Fuji Pharma Co., Ltd. Submits Application for Marketing Approval of First Biosimilar Candidate in Japan	17/22/17	CI
Fuji Pharma Co., Ltd. Provides Financial Guidance for the Fiscal Year Ending September 30, 2022	18/21/18	CI
Fuji Pharma Provides Dividend Guidance for the Fiscal Year Ending September 30, 2022	18/21/18	CI
Fuji Pharma Co., Ltd. Announces Consolidated Earnings Results for the First Half of Fiscal Year Ending September 30, 2021	20/21/20	CI
Mitsui Withdraws Shareholder Proposal to Fuji Pharma	17/21/17	CI
Tranche Update on Fuji Pharma Co., Ltd.'s Equity Buyback Plan announced on February 9, 2021.	10/21/10	CI
Fuji Pharma Co., Ltd.'s Equity Buyback announced on February 9, 2021, has expired with 6,875,000 shares, representing 22.06% for ¥9,391.25 million.	10/21/10	CI
Fuji Pharma Co., Ltd. announces an Equity Buyback for 7,320,600 shares, representing 23.47% for ¥10,000 million.	09/21/09	CI
Fuji Pharma Co., Ltd. authorizes a Buyback Plan.	09/21/09	CI
Mitsui Submits Shareholder Proposal to Fuji Pharma	13/20/13	CI
Fuji Pharma Co., Ltd. Reports Consolidated Earnings Results for the Three Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Six Months Ending March 31, 2020 and Fiscal Year Ending September 30, 2020; Provides Dividend Guidance for the Second Quarter Ending March 31, 2020 and Fiscal Year Ending September 30, 2020	06/20/06	CI
Fuji Pharma Co., Ltd. Announces Consolidated Earnings Results for the Year Ended September 30, 2019; Provides Earnings Guidance for the Six Months and Year Ending September 30 2020; Announces Dividend for the Year Ended September 30, 2019, Payable on December 20,2019; Provides Second Quarter and Year End Dividend Guidance for the Year Ending September 30, 2020	08/19/08	CI
Fuji Pharma Co., Ltd. Announces Consolidated Earnings Results for the Nine Months Ended June 30, 2019; Provides Earnings Guidance for the Year Ending September 30, 2019; Provides Year End Dividend Guidance for the Year Ending September 30, 2019	08/19/08	CI

Fuji Pharma Co., Ltd. is a Japan-based company mainly engaged in the manufacture and sale of medical products. The Company is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Fuji Pharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,457 JPY

Average target price

2,057 JPY

Spread / Average Target

+41.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FUJI PHARMA CO., LTD.	-16.22%	23Cr
ELI LILLY AND COMPANY	+39.22%	73TCr
NOVO NORDISK A/S	+30.57%	59TCr
JOHNSON & JOHNSON	-7.85%	35TCr
MERCK & CO., INC.	+15.48%	32TCr
ABBVIE INC.	-0.12%	27TCr
ASTRAZENECA PLC	+12.55%	24TCr
NOVARTIS AG	+6.65%	20TCr
ROCHE HOLDING AG	-6.09%	20TCr
PFIZER, INC.	-3.37%	16TCr

Other Pharmaceuticals